A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia
- PMID: 10803796
- DOI: 10.1097/00002826-200003000-00003
A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia
Abstract
In clinical trials for patients with Parkinson's disease (PD) with motor fluctuations, efficacy is generally ascribed to an intervention if motor function is significantly improved or if "off" time is significantly reduced. However, we have argued that patients might not be improved if off time is reduced only to the extent that unwanted dyskinesia is increased. Therefore, a home diary should include an assessment of dyskinesia to provide an accurate reflection of clinical status over a period of time. We undertook two studies to develop a home diary to assess functional status in patients with PD with motor fluctuations and dyskinesia. In both studies, patients concurrently completed a test and a reference diary. In Study I, we evaluated the impact of different severities of dyskinesia on patient-defined functional status. There were 1,149 evaluable half-hour time periods from 24 patients; 94.3% of off time was considered "bad" time and 90.2% of "on" time without dyskinesia, 72.6% of on time with mild dyskinesia, 43.0% of on time with moderate dyskinesia, and 15.2% of on time with severe dyskinesia was considered "good" time. In Study II, we evaluated a new home diary designed to separate dyskinesia that had a negative impact on patient-defined functional status from dyskinesia that did not. There were 816 evaluable time periods from 17 patients; 84.9% of off time and 89.9% of on time with troublesome dyskinesia was considered bad time while 85.5% of on time without dyskinesia and 93.8% of on time with nontroublesome dyskinesia was considered good time. With this diary (Diary II), the effect of an intervention can be expressed as the change in off time and the change in on time with troublesome dyskinesia (bad time). The sum can be used as an outcome variable and compared to baseline or across groups. In evaluating the efficacy of an intervention, assessment of change in off time and change in on time with troublesome dyskinesia provides a more accurate reflection of clinical response than change in off time alone.
Similar articles
-
Carbidopa and Levodopa Extended Release Capsules in Patients with and without Troublesome and Non-Troublesome Dyskinesia.J Parkinsons Dis. 2020;10(3):915-925. doi: 10.3233/JPD-202010. J Parkinsons Dis. 2020. PMID: 32568108 Free PMC article.
-
Parkinson's disease home diary: further validation and implications for clinical trials.Mov Disord. 2004 Dec;19(12):1409-13. doi: 10.1002/mds.20248. Mov Disord. 2004. PMID: 15390057
-
Patient evaluation of a home diary to assess duration and severity of dyskinesia in Parkinson disease.Clin Neuropharmacol. 2006 Nov-Dec;29(6):322-30. doi: 10.1097/01.WNF.0000229546.81245.7F. Clin Neuropharmacol. 2006. PMID: 17095895
-
Motor fluctuations and dyskinesia in Parkinson's disease.Parkinsonism Relat Disord. 2001 Oct;8(2):101-8. doi: 10.1016/s1353-8020(01)00024-4. Parkinsonism Relat Disord. 2001. PMID: 11489675 Review.
-
[Influence of levodopa, stalevo on dyskinesia in Parkinson's disease: STRIDE-PD study].Zh Nevrol Psikhiatr Im S S Korsakova. 2013;113(7 Pt 2):62-8. Zh Nevrol Psikhiatr Im S S Korsakova. 2013. PMID: 23994933 Review. Russian.
Cited by
-
Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results.Mov Disord. 2015 Apr;30(4):500-9. doi: 10.1002/mds.26123. Epub 2014 Dec 24. Mov Disord. 2015. PMID: 25545465 Free PMC article. Clinical Trial.
-
Carbidopa and Levodopa Extended Release Capsules in Patients with and without Troublesome and Non-Troublesome Dyskinesia.J Parkinsons Dis. 2020;10(3):915-925. doi: 10.3233/JPD-202010. J Parkinsons Dis. 2020. PMID: 32568108 Free PMC article.
-
Levodopa-induced dyskinesia in Parkinson's disease: epidemiology, etiology, and treatment.Curr Neurol Neurosci Rep. 2007 Jul;7(4):302-10. doi: 10.1007/s11910-007-0046-y. Curr Neurol Neurosci Rep. 2007. PMID: 17618536 Review.
-
Dopamine receptor agonists for the treatment of early or advanced Parkinson's disease.CNS Drugs. 2010 Nov;24(11):941-68. doi: 10.2165/11537810-000000000-00000. CNS Drugs. 2010. PMID: 20932066 Review.
-
Quantitative Assessment of Parkinsonian Tremor Based on an Inertial Measurement Unit.Sensors (Basel). 2015 Sep 29;15(10):25055-71. doi: 10.3390/s151025055. Sensors (Basel). 2015. PMID: 26426020 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials